- to articulate (a speech sound, especially a stop) so as to produce an audible puff of breath, as with the first t of total, the second t being unaspirated.
- to articulate (the beginning of a word or syllable) with an h -sound,as in which, pronounced (hwich), or hitch as opposed to witch or itch.
- Stimulating your own immune system to work harder or smarter to attack cancer cells
- Giving you immune system components, such as man-made immune system proteins
Infusion pumps may be capable of delivering fluids in large or small amounts, and may be used to deliver nutrients or medications – such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers.
Some infusion pumps are designed mainly for stationary use at a patient’s bedside. Others, called ambulatory infusion pumps, are designed to be portable or wearable.
The atomic number is the number of protons in an atom's nucleus. Atomic mass adds to that the number of neutrons in the nucleus. Each element has a typical atomic mass, but when the number of protons stays the same and the number of neutrons changes, you have an isotope. These can be stable, like Deuterium, an isotope of Hydrogen that has one extra neutron, or they can be radioactive, like Plutonium-239, which is a component of nuclear waste.
In medicine, a port is a small medical appliance that is installed beneath the skin. A catheter connects the port to a vein. Under the skin, the port has a septum through which drugs can be injected and blood samples can be drawn many times, usually with less discomfort for the patient than a more typical "needle stick".
Ports are used mostly to treat hematology and oncology patients. Ports were previously adapted for use in hemodialysis patients, but were found to be associated with increased rate of infections and are no longer available in the US.[1]
The port is usually inserted in the upper chest (known as a "chest port"), just below the clavicle or collar bone, leaving the patient's hands free.
MIBG Therapy
Metaiodobenzylguanidine (MIBG) is a compound that can be combined with radioactive iodine (I-131) to deliver targeted radiation therapy. I-131 MIBG can be used to treat high-risk neuroblastoma, a cancerous tumor that begins in nerve tissue of infants and very young children. MIBG therapy is generally more effective, less painful, and requires less time in the hospital than other treatment options.
Originally developed as a blood pressure medication, MIBG is a compound that is absorbed by certain types of nerve tissue, including neuroblastoma cells. For many years, it has been used diagnostically to determine where cancerous activity is occurring within the body.
More recently, oncologists began using it to deliver targeted radiation to neuroblastoma. I-131 MIBG is administered to a child through an intravenous line and absorbed by tumor cells, which are killed by radiation emitted by the radioactive I-131. This therapy destroys tumors while sparing normal, healthy tissue. MIBG therapy is currently used to treat relapsed or refractory neuroblastoma and is being studied as a treatment for newly diagnosed high-risk patients.
I-131 MIBG is well tolerated. The major side effect of therapy is low blood counts. A large study showed that 30-40 percent of children with relapsed neuroblastoma respond to MIBG therapy, which makes it one of the most active agents for relapsed disease. While it doesn’t cure neuroblastoma, I-131 MIBG allows patients to gain control of their disease and provide the possibility of prolonged disease stabilization.
The tumors are usually noncancerous (benign), but sometimes can become cancerous (malignant). Symptoms are often mild. However, complications of neurofibromatosis can include hearing loss, learning impairment, heart and blood vessel (cardiovascular) problems, loss of vision, and severe pain.
As a sump tube where the physician desires to keep the stomach continuously and completely evacuated of swallowed air, swallowed saliva, gastric secretions or fresh blood the nasogastric (NG) tube is used with a vacuum source. The original Levin tube failed Dr. Harold W. Andersen in 1958 and he endeavored to engineer a double lumen NG tube to reduce the vacuum of the aspiration lumen by adding a vent lumen to the outside including an anti-reflux filter at the proximal end of the vent lumen and additional markings for placing the tube in the patient. This was the first double-lumen nasogastric tube.
Also indicated for the symptomatic relief of itch associated with chickenpox.
Read more: http://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/stem-cell-transplant/harvesting-stem-cells/?region=on#ixzz4S6I53iHX